Company intelligence / Profile preview
JD Bioscience
Gwangju, Gwangju, South Koreajdbiosci.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Phase 1
01
Overview
JD Bioscience has a robust pipeline with first-in-class drug candidates targeting high unmet needs in metabolic and related diseases. The company’s lead program is advancing through early clinical development for NASH; other programs are at preclinical or discovery stages. No published pivotal results yet.
- Therapeutic areas
- GastroenterologyImmunologyEndocrinologyOtherOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesAntibody-drug conjugates (ADC)Proteolysis-targeting chimeras (PROTAC)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
~15 external research collaboration partners focused on medicinal chemistry; specific names not disclosed
Beyond the preview
Go deeper on JD Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JD Bioscience.